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OBJECTIVES: Drotrecogin alfa (activated) (DrotAA) is indi-
cated for adults with severe sepsis (SS) at high risk of death. ICD-
9-CM code 995.92 for SS became available in October 2002.
The purpose of our study was to determine whether hospital
length-of-stay (LOS) and costs differ for adult patients most
likely to have SS, depending on whether they received DrotAA.
METHODS: We conducted a retrospective analysis of
2002–2003 hospital discharges from the large Premier Inc Per-
spective Comparative Database developed for clinical and eco-
nomic benchmarking. We modeled adult patients’ propensity for
having code 995.92 as proxy for likelihood of having SS. Among
patients having the highest likelihood of SS, deﬁned as the top
5% of propensity scores, we compared hospital LOS and costs
between DrotAA recipients and non-recipients. We also com-
pared LOS and costs stratiﬁed on the interval between evident
SS and initiation of DrotAA: Same-day, Next-day, Day2+.
RESULTS: Of 218,805 patients, 11,218 met the criterion for
highest likelihood of having SS. Whereas 67.2% of these never
received DrotAA, 38.3% of DrotAA recipients were Same-day,
31.4% Next-day, and 30.4% Day2+. Hospital LOS was shorter
among DrotAA recipients than non-recipients overall (21.0 vs.
22.1 days; p = 0.029). Moreover, for DrotAA patients, hospital
LOS shortened as the interval shortened (Same-day 16.6, Next-
day 19.2, Day2+ 30.4 days; p < 0.0001). Hospital costs were
higher for DrotAA recipients than non-recipients overall
($57,834 vs. $54,145; p = 0.004). However, for DrotAA
patients, hospital costs were lower as the interval shortened
(Same-day $44,134; Next-day $52,205; Day2+ $86,669; p <
0.0001), consistent with LOS differences. CONCLUSIONS:
Most patients with the highest likelihood of having SS never
receive DrotAA. Hospital LOS and costs signiﬁcantly decrease
as the treatment interval shortens for DrotAA recipients,
although DrotAA recipients have higher average hospital costs
than non-recipients overall. Hospital LOS and costs might be
reduced through improvements to the appropriate use of
DrotAA.
INFECTION—Health Care Use & Policy Studies
PIN19
A RETROSPECTIVE EVALUATION OF THE MANAGEMENT
AND OUTCOMES IN HOSPITALIZED PATIENTS WITH
COMMUNITY ACQUIRED PNEUMONIA IN AN INNER-CITY
HOSPITAL
Sakalis E1, Pan L2, Wong SL3
1Bellevue Hospital Medical Center, New York, NY, USA, 2Ludwig
Institue For Cancer Research, New York, NY, USA, 3Pﬁzer Inc, Syosset,
NY, USA
OBJECTIVES: This study evaluated the medical management of
patients hospitalized with Community Acquired Pneumonia
(CAP) in an inner-city hospital comprising over 90% of Medic-
aid and indigent patients. The goal was to identify opportunities
for quality improvement. METHODS: A random sample of
patients with a diagnosis of CAP at discharge in 2002 was
selected for retrospective chart review. Data was collected based
on American Thoracic Society (ATS) criteria. RESULTS: Medical
records of 155 patients were reviewed; mortality rate was 4%.
The percentage of patients receiving the ﬁrst antibiotic dose in
less than eight hours was 80. Ninety-seven percent of patients
had oxygenation checked within 24 hours of admission. Only
45% of patients had blood cultures performed, and 91% of these
were positive. The most common antibiotic prescribed was oral
levoﬂoxacin representing 39% of all antibiotic orders. Using 
the ATS guidelines, 14 patients (9%) were considered to have
received inappropriate antimicrobial treatment. Of these, 7 had
severe cases of CAP requiring treatment in the Intensive Care
Unit (ICU). The most common cause for non-compliance in the
ICU was lacked of coverage for atypical microbes. The average
length of stay for all patients in the study was 7.64 days (SD +/-
0.327). Patients who received a antibiotic regimen which com-
plied with guidelines, as compared to those who did not, had a
shorter length of study in the hospital (7.33 days vs 9.79 days,
p = 0.31). CONCLUSION: Ongoing analysis will provide
further improvement in clinical outcomes and will identify areas
of focus for future research.
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OBJECTIVES: Contemporary community-acquired pneumonia
(CAP) guidelines recommend that intensive care unit (ICU)
patients empirically receive a beta-lactam plus a macrolide
(BLM) or a beta-lactam plus a ﬂuoroquinolone (BLF). This study
compares the impact of the initial antibiotic choice on time to
clinical stability (TTCS), time to switch therapy (TTST), length
of hospital stay (LOS), and in-hospital mortality. METHODS:
Patient demographics, laboratory and physical exam ﬁndings,
empiric antibiotic therapy, and hospital course (over 200 vari-
ables in all) were extracted from the medical records of all adult
CAP patients admitted to the ICUs of 5 community hospitals
between 1 November 1999 and 30 April 2000. Patients were
divided into two groups (BLM and BLF) based on antibiotics
received within the ﬁrst 24h of hospitalization. TTCS, TTST,
LOS and in-hospital mortality were compared using regression
models that included the outcome as the dependent variable,
antibiotic therapy as the independent variable, and Pneumonia
Severity of Index (PSI score) as a covariate. RESULTS: Overall,
there were 129 ICU patients of which 34% received BLF and
13% received BLM. Groups were similar with respect to age,
sex, comorbidities, PSI score, pre-admission antibiotics, shock,
acute renal failure, and the need for mechanical ventilation.
Compared to patients who received BLM, those who received
BLF had a signiﬁcantly longer (median; OR, 95%CI) TTCS 
(2 vs. 4 days; 1.54, 1.04–2.20), TTST (6 vs. 10 days; 1.47,
1.06–2.00), and LOS (6.5 vs. 12 days; 1.58, 1.11–2.11). In-hos-
pital mortality was similar between patients who received BLM
and BLF (13% vs. 15%; 1.17, 0.23–8.95). CONCLUSION:
Severe CAP patients who initially received a beta-lactam plus a
macrolide had a faster time to clinical stability, shorter time to
switch therapy, and reduced time to hospital discharge compared
to patients treated with a beta-lactam plus a ﬂuoroquinolone.
